Biocon Ltd's Q4FY25 Quarter Results
- 09 May 2025
Result Summary
- Biocon Ltd reported a 2.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.9%.
- Its expenses for the quarter were down by 2.2% QoQ and up 7.3% YoY.
- The net profit increased 174.8% QoQ and decreased 46.2% YoY.
- The earnings per share (EPS) of Biocon Ltd stood at 1.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3965.70 | 3856.20 | 3928.80 | 2.8% | 0.9% |
Total Expenses | 3635.20 | 3718.40 | 3389.10 | -2.2% | 7.3% |
Profit Before Tax | 321.70 | 155.90 | 536.70 | 106.4% | -40.1% |
Tax | 96.10 | 74.80 | 82.10 | 28.5% | 17.1% |
Profit After Tax | 222.90 | 81.10 | 414.50 | 174.8% | -46.2% |
Earnings Per Share | 1.10 | 0.20 | 2.60 | 450.0% | -57.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Biocon Ltd is a leading biopharmaceutical company based in India, primarily engaged in the development and manufacturing of biologics. Its core business areas include biopharmaceuticals, research services, and novel biologics. The company is recognized for its significant contributions to healthcare through the development of affordable biosimilars for chronic diseases such as diabetes, cancer, and autoimmune conditions. Biocon has a global presence with operations in key markets including the United States, Europe, and emerging markets. Recent developments have seen the company expanding its portfolio and strengthening its market position through strategic partnerships and product launches.
Revenue
In the fourth quarter of the fiscal year 2025, Biocon Ltd reported a total income of ₹3965.70 crores. This represents an increase of 2.8% compared to the previous quarter (Q3FY25), where the total income was ₹3856.20 crores. When compared to the same quarter the previous year (Q4FY24), there was a modest year-over-year increase of 0.9%, as the total income for Q4FY24 was ₹3928.80 crores. These figures indicate a steady revenue stream for the company, highlighting its ability to maintain growth across consecutive quarters and sustain its market position over the year.
Profitability
Biocon Ltd's profitability metrics for Q4FY25 show a notable increase in profit before tax, which stood at ₹321.70 crores. This represents a significant quarter-over-quarter growth of 106.4%, up from ₹155.90 crores in Q3FY25. However, the profit before tax decreased by 40.1% compared to Q4FY24, where it was ₹536.70 crores. The profit after tax in Q4FY25 was ₹222.90 crores, marking a substantial quarter-over-quarter increase of 174.8% from ₹81.10 crores in Q3FY25, but a decline of 46.2% from ₹414.50 crores in Q4FY24. The company's earnings per share (EPS) in Q4FY25 was ₹1.10, reflecting a 450.0% increase from Q3FY25, though it was down by 57.7% from Q4FY24's ₹2.60.
Operating Metrics
The total expenses for Biocon Ltd in Q4FY25 amounted to ₹3635.20 crores, which is a decrease of 2.2% from the previous quarter (Q3FY25) where expenses were ₹3718.40 crores. Year-over-year, there was an increase of 7.3% in total expenses compared to ₹3389.10 crores in Q4FY24. The tax expense for Q4FY25 was ₹96.10 crores, showing a quarter-over-quarter increase of 28.5% from Q3FY25 and a year-over-year increase of 17.1% from Q4FY24. These metrics reflect the company's operational cost management and tax obligations during the quarter, providing insight into its financial efficiency and strategic fiscal planning.
